Mylan Settles Dispute Over Generic Orapred ODT
Mylan Inc. has entered into a licensing agreement that will allow it to sell its generic version of anti-inflammatory Orapred ODT, ending a patent infringement dispute with rivals Shionogi Pharma Inc....To view the full article, register now.
Already a subscriber? Click here to view full article